We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Shoal Point Energy Ltd | CSE:SHP | CSE | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.04 | 0.035 | 0.045 | 0 | 01:00:00 |
DUBLIN, May 2, 2013 /PRNewswire/ --
Shire delivers 10% increase in Non GAAP earnings; full year EPS guidance in line with consensus(1)
Shire (LSE: SHP, NASDAQ: SHPG) announces results for the three months to March 31, 2013.
Reported Financial Highlights Q1 2013 Growth(2) $1,117 Product sales million +1%(3) $1,162 Total revenues million -1%(3) Non GAAP operating income $393 million +9%(3) US GAAP operating income $129 million -56%(4) Non GAAP diluted earnings per ADS $1.63 +10%(3) US GAAP diluted earnings per ADS $0.35 -72%(3) Non GAAP cash generation $257 million -17%(3) Non GAAP free cash flow $113 million -54%(3) US GAAP net cash provided by operating activities $160 million -38%(3)
(1) See page 4 for assumptions.
(2) Percentages compare to equivalent 2012 period.
(3) Percentage growth on a Constant Exchange Rate ("CER") basis is in line with the reported growth for the quarter.
(4) US GAAP operating income includes the impact of goodwill impairment, see page 11 for details.
The Non GAAP financial measures included within this release are explained on page 21, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 18 - 20.
Flemming Ornskov, M.D., Chief Executive Officer, commented:
"In Q1 2013 we experienced continued strong performance from VYVANSE, INTUNIV, LIALDA, VPRIV and FIRAZYR offset by the challenge of lower sales of DERMAGRAFT and REPLAGAL which we are actively managing. We generated $257 million of cash during the quarter and delivered 10% Non GAAP earnings growth while investing in our R&D pipeline.
Shire has consistently delivered growth significantly above the industry levels of mid single digit and we intend that this will be the case in the future. As we look forward to the remainder of the year, we continue to expect to deliver earnings growth in line with current consensus earnings expectations for 2013 (1).
On becoming Shire Chief Executive Officer, I am pleased to confirm the direction we will take, in order to continue to deliver significantly above industry average growth. We intend to continue to be a high-growth innovation business providing differentiated specialist medicines in areas of high unmet need for patients treated by specialist physicians. Shire's strategic priorities are to grow sales of our existing portfolio and to bring new innovative treatments to market through both R&D and Business Development.
To deliver this we are evolving the way the business works, introducing a flatter and more scalable structure of initially five commercially focused business units (Rare Diseases, Neuroscience, GI, Regenerative Medicine and Internal Medicine) and a single R&D organization supported by centralized corporate functions.
In the first quarter we added to our pipeline with three acquisitions: Lotus Tissue Repair, Premacure and SARcode BioSciences. The last two provide us with the foundation to build a potential new business unit in ophthalmology - a growing market with many unmet patient needs. We're reviewing our pipeline to prioritize investment in our innovative, late stage pipeline assets. We also aim to focus our business development on acquiring later stage assets and to grow our sales in Latin America and Asia.
As the new Chief Executive, I am excited by the potential opportunities for delivering even greater value to Shire's patients and shareholders and I look forward to updating you in the many quarters to come."
SHIRE STRATEGY
Flemming Ornskov, Chief Executive Officer ("CEO") today sets out his strategy for Shire's future and outlines a re-alignment of its business structure to drive future growth and innovation. Shire will continue to grow through focusing on its core strengths of developing and marketing innovative specialist medicines to meet significant unmet patient needs.
The growth strategy will be delivered through a sharpened focus on two key priorities:
These priorities will be underpinned by a simplification of the business structure in order to drive commercial excellence and pipeline innovation. Shire will have an "In-Line" marketed product group and a "Pipeline" group, supported by a single technical operations group and simplified, centralized corporate functions.
Delivering the strategy
The newly established "In-Line" marketed products group will consist of five business units ("BU"s) focused exclusively on commercial delivery; Rare Diseases, Neuroscience (formerly Behavioral Health), Gastrointestinal ("GI"), Regenerative Medicine ("RM") and Internal Medicine. More BUs will be formed when significant assets are either acquired or reach the appropriate stage of development.
The Pipeline group, consisting of R&D and BD, will prioritize its activities towards late stage development programs. Pre-clinical development focus will be primarily in rare diseases. As part of the delivery of this strategy, Shire's R&D will be led by a single R&D organization. BD will continue to be a key activity for Shire, focused on identifying later stage development programs and in market products in target specialist areas.
In addition to chairing a newly formed Executive Committee, Flemming Ornskov will also chair the "In-Line" and "Pipeline" group teams, which will be the engines accountable for driving the profitable growth.
Geographic expansion
Shire will work to increase profitability of its existing international business while also investing in Asia and Latin America. Plans are underway for more focused growth in Japan where Shire recently announced the establishment of a new office, and in Brazil which is already the 5th largest country for Shire's rare disease business sales. China has also been identified as a priority and Shire is evaluating options for expanding more of the business into this dynamic market.
FINANCIAL SUMMARY
First Quarter 2013 Unaudited Results
Q1 2013 Q1 2012 Non Non US GAAP Adjustments GAAP US GAAP Adjustments GAAP $M $M $M $M $M $M Total revenues 1,162 - 1,162 1,172 - 1,172 Operating income 129 264 393 295 67 362 Diluted earnings per ADS $0.35 $1.28 $1.63 $1.24 $0.24 $1.48
OUTLOOK
We reiterate our confidence in delivering Non GAAP earnings growth in line with consensus earnings expectations for 2013(1).
For the full year we now anticipate product sales growth in the mid-to-high single digits. The rate of growth in total product sales will improve from that seen in the first quarter as our portfolio continues to deliver growth and we benefit from an easing of comparatives over the second half of the year.
Specifically we expect ELAPRASE to post double digit growth for the full year and we expect REPLAGAL sales to recover from the first quarter decline to be more in line with 2012 for the full year. We expect DERMAGRAFT to return to growth in the second half but sales for the full year will still be lower than in 2012.
We continue to expect Royalties and other revenues to be 30-40% lower than 2012, and our Non GAAP gross margin is expected to remain at a similar level to 2012.
We expect low-to-mid teens growth in Non GAAP R&D as we continue to invest increasing amounts in our promising pipeline and to progress our late stage clinical trials. As a result of lower Non GAAP SG&A in Q1, and continued careful management of our cost base, we now expect Non GAAP SG&A for the full year to be marginally lower than 2012. Taken together, we now expect low single digit growth in combined Non GAAP R&D and SG&A, creating operating leverage for the full year.
Our core effective tax rate on Non GAAP income is anticipated to remain in the range of 18-20%.
As we look forward to the remainder of the year, we continue to expect to deliver earnings growth in line with current consensus earnings expectations for 2013 (1).
FIRST QUARTER 2013 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS
Products
VYVANSE - for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD")
DERMAGRAFT - for the treatment of Diabetic Foot Ulcers ("DFU") in Canada
VPRIV - for the treatment of Gaucher disease (Type 1)
Pipeline
Lisdexamfetamine dimesylate(1) ("LDX") - for the treatment of negative symptoms of schizophrenia ("NSS")
(1) Currently marketed as VYVANSE in the US and ELVANSE® in certain territories in the EU for the treatment of ADHD.
HGT4510 - for Duchenne Muscular Dystrophy ("DMD")
VASCUGEL® - for the treatment of end-stage renal disease.
OTHER DEVELOPMENTS
Legal Proceedings
INTUNIV patent litigation
Acquisition of SARcode Bioscience Inc. ("SARcode")
Acquisition of Premacure AB ("Premacure")
Acquisition of Lotus Tissue Repair, Inc. ("Lotus")
Share buy-back Program
BOARD AND COMMITTEE CHANGES
ADDITIONAL INFORMATION
The following additional information is included in this press release:
Page Overview of First Quarter 2013 Financial Results 8 Financial Information 12 Non GAAP Reconciliation 18 Notes to Editors 20 Safe Harbor Statement 21 Explanation of Non GAAP Measures 21 Trade marks 22
Dial in details for the live conference call for investors 13:00 BST / 08:00 EDT on May 2, 2013:
UK dial in: 0808-237-0030 or 0203-139-4830
US dial in: 1-866-928-7517 or 1-718-873-9077
International Access Numbers: Click here
Password/Conf ID: 29454716#
Live Webcast: Click here
OVERVIEW OF FIRST QUARTER 2013 FINANCIAL RESULTS
1. Product sales
For the three months to March 31, 2013 product sales increased by 1% to $1,117 million (Q1 2012: $1,107 million) and represented 96% of total revenues (Q1 2012: 94%).
US Exit Market Year on year growth Share(1) Non GAAP Product sales Sales $M Sales CER US Rx(1) VYVANSE 298.4 +15% +15% +6% 17% ELAPRASE 114.3 -9% -9% n/a(2) n/a(2) REPLAGAL 114.0 -15% -15% n/a(3) n/a(3) LIALDA/MEZAVANT 100.5 +12% +12% +9% 23% VPRIV 81.6 +14% +14% n/a(2) n/a(2) INTUNIV 77.7 +13% +13% +12% 4% PENTASA(R) 71.0 +8% +8% -3% 14% FIRAZYR 41.7 +112% +111% n/a(2) n/a(2) DERMAGRAFT 18.5 -62% -62% n/a(2) n/a(2) OTHER 99.2 -11% -11% n/a n/a Excluding ADDERALL XR 1,016.9 +2% +2% ADDERALL XR 99.8 -10% -10% -20% 5% Total 1,116.7 +1% +1%
(1) Data provided by IMS Health National Prescription Audit ("IMS NPA"). Exit market share represents the average monthly US market share in the month ended March 31, 2013.
(2) IMS NPA Data not available.
(3) Not sold in the US in Q1 2013.
VYVANSE - ADHD
VYVANSE product sales showed strong growth (up 15%) in Q1 2013 compared to Q1 2012, primarily as a result of higher prescription demand (up 6%) and the effect of a price increase taken since Q1 2012. Shire also experienced further destocking in the retail channel which was offset by the positive impact of some shipment slippage from Q4 2012.
ELAPRASE- Hunter syndrome
Product sales from ELAPRASE in Q1 2013 were down 9% compared to Q1 2012 due to the impact of the timing of large orders to certain markets which order less frequently. The underlying number of patients being treated with ELAPRASE continues to grow.
REPLAGAL - Fabry disease
REPLAGAL sales for the quarter were down 15% primarily due to the impact of ordering patterns in Latin America and lower volumes in Europe, where the impact of increased competition outweighed the continued growth in new naïve patients. On a global basis, total patient numbers continue to show good long term growth.
LIALDA/MEZAVANT - Ulcerative colitis
Product sales for LIALDA/MEZAVANT increased (up 12%) in Q1 2013 primarily due to higher market share in the US and the effect of a price increase taken since Q1 2012. These positive factors were to a lesser extent offset by the effect of higher US sales deductions and higher destocking at the retail level.
VPRIV - Gaucher disease
Growth in VPRIV product sales (up 14%) in Q1 2013 was driven by the continued growth in the number of patients on therapy.
INTUNIV - ADHD
The strong growth in INTUNIV product sales (up 13%) in Q1 2013 was driven by growth in US prescription demand (up 12%) and the effect of price increases taken since Q1 2012. These positive factors were partially offset by the effect of destocking in Q1 2013 as compared to slight stocking in Q1 2012.
PENTASA - Ulcerative colitis
PENTASA product sales (up 8%) benefited from price increases taken since Q1 2012, the impact of which was moderated by a small amount of retail pipeline destocking in Q1 2013.
FIRAZYR - Hereditary Angioedema ("HAE")
The significant growth in FIRAZYR sales (up 112%) reflects the continued success of the product in the US market.
DERMAGRAFT - DFU
DERMAGRAFT product sales were down 62%, reflecting the impact of an ongoing restructuring of the RM sales and marketing organization and the implementation of a new commercial model. Whilst our future expectations for long term growth of DERMAGRAFT have been revised downwards, we still expect the product to return to growth over coming quarters.
ADDERALL XR - ADHD
ADDERALL XR product sales decreased (down 10%) in Q1 2013 primarily as a result of lower US prescription demand (down 20%) following the introduction of a new generic competitor in Q2 2012 and to a lesser extent the effect of higher sales deductions as a percentage of sales in Q1 2013 compared to Q1 2012. These negative factors were partially offset by the benefit of a price increase taken since Q1 2012.
2. Royalties
Year on year growth Royalties to Product Shire $M Royalties CER 3TC(R) and ZEFFIX(R) 1.00 12.5 -8% -8% FOSRENOL(R) 1.00 9.0 -10% -10% ADDERALL XR 1.00 8.1 -68% -68% Other 1.00 8.9 +20% +18% Total 1.00 38.5 -32% -32%
As expected, royalty income from 3TC and ZEFFIX continued to decline due to increased competition from other products and the expiry of patents in certain territories.
Royalties from ADDERALL XR in Q1 2013 were significantly impacted by reduced sales volume as well as a lower royalty rate payable on sales of authorized generic ADDERALL XR by Impax, since the launch of a new generic version in Q2 2012.
3. Financial details
Cost of product sales
% of % of product product Q1 2013 sales Q1 2012 sales $M $M Cost of product sales (US GAAP) 155.9 14% 158.4 14% Depreciation (7.8) (7.2) Cost of product sales (Non GAAP) 148.1 13% 151.2 14%
Non GAAP cost of product sales as a percentage of product sales decreased slightly in Q1 2013, due to improved margins in the ADHD portfolio which were only partially offset by lower margins on other products.
Research and Development ("R&D")
% of % of product product Q1 2013 sales Q1 2012 sales $M $M R&D (US GAAP) 224.2 20% 220.3 20% Payments in respect of in-licensed and acquired products - (23.0) Depreciation (4.6) (6.4) R&D (Non GAAP) 219.6 20% 190.9 17%
Non GAAP R&D increased by $28.7 million, or 15%, due to our increased investment in a number of targeted R&D programs including non-ADHD programs for LDX, and spend on SPD602 for Iron Overload and SRM003 for Acute Vascular Repair, acquired since Q1 2012.
US GAAP R&D increased by $3.9 million, or 2%, a lower rate of increase than on a Non GAAP basis as Q1 2012 included payments in respect of acquired and in-licensed products, not repeated in Q1 2013.
Selling, General and Administrative ("SG&A")
% of % of product product 2013 sales 2012 sales $M $M SG&A (US GAAP) 438.7 39% 500.0 45% Intangible asset amortization (45.9) (45.6) Legal and litigation costs(1) (4.2) - Depreciation (16.7) (13.6) SG&A (Non GAAP) 371.9 33% 440.8 40%
Non GAAP SG&A decreased by $68.9 million, or 16%, partly due to the benefit of actions taken during last year, in addition to careful management of our cost base. The rate of decline in SG&A in Q1 2013 was accentuated by the high level of SG&A in Q1 2012 relative to the level of spend in subsequent quarters in 2012.
US GAAP SG&A decreased by $61.3 million, or 12% primarily due to legal and litigation costs excluded from Non GAAP SG&A in Q1 2013.
Goodwill impairment charges
For the three months to March 31, 2013 Shire recorded an impairment charge for goodwill of $198.9 million (Q1 2012: $nil) relating to Shire's RM business. Following a review of future forecasts for the RM business unit, management determined in Q1 2013 that future sales are now expected to be lower than anticipated at the time of acquisition and consequently in accordance with US GAAP, it has been determined that the goodwill attributable to the RM business unit is impaired. Whilst our future expectations for long term growth of DERMAGRAFT have been revised downwards, we still expect the product to return to growth over coming quarters.
Gain on sale of product rights
For the three months to March 31, 2013 Shire recorded a gain on sale of product rights of $6.5 million (2012: $7.2 million) following re-measurement of the contingent consideration receivable from the divestment of DAYTRANA®.
Reorganization costs
For the three months to March 31, 2013 Shire recorded reorganization costs of $17.5 million (Q1 2012: $nil) relating to the collective dismissal and closure of Shire's facility at Turnhout, Belgium.
Integration and acquisition costs
For the three months to March 31, 2013 Shire recorded integration and acquisition costs of $4.1 million primarily associated with the acquisition of Lotus and integration of FerroKin Biosciences, Inc. ("FerroKin") in addition to charges related to the change in fair value of deferred contingent consideration. In Q1 2012 integration and acquisition costs ($5.3 million) primarily related to the integration of Advanced BioHealing Inc. ("ABH").
Interest expense
For the three months to March 31, 2013 Shire incurred interest expense of $9.1 million (Q1 2012: $10.2 million). Interest expense in Q1 2013 principally relates to the coupon on Shire's $1,100 million 2.75% convertible bonds due 2014.
Taxation
The effective rate of tax on Non GAAP income in Q1 2013 was 19% (Q1 2012: 20%), and on a US GAAP basis the effective rate of tax was 46% (Q1 2012: 17%).
The effective rate of tax in Q1 2013 on a Non GAAP basis is lower than the same period in 2012 due primarily to the recognition of the 2012 US R&D credit in the first quarter of 2013, partially offset by adverse changes in profit mix. The US R&D credit was recognized in Q1 2013 following the enactment of legislation on January 2, 2013, approving the extension of the regular R&D credit retrospectively.
The effective rate of tax in Q1 2013 on a GAAP basis is higher than the same period in 2012 primarily due to the impact of the impairment of RM goodwill which is non-deductible for tax purposes, an increase in unrecognised tax losses and adverse changes in profit mix but partially offset by the recognition of the 2012 US R&D credit in the first quarter of 2013.
FINANCIAL INFORMATION
Page Unaudited US GAAP Consolidated Balance Sheets 13 Unaudited US GAAP Consolidated Statements of Income 14 Unaudited US GAAP Consolidated Statements of Cash Flows 15 Selected Notes to the Unaudited US GAAP Financial Statements (1) Earnings per share 16 (2) Analysis of revenues 17 Non GAAP reconciliation 18
Unaudited US GAAP financial position as of March 31, 2013
Consolidated Balance Sheets
March 31, December 31, 2013 2012 $M $M ASSETS Current assets: Cash and cash equivalents 1,450.7 1,482.2 Restricted cash 19.3 17.1 Accounts receivable, net 884.4 824.2 Inventories 471.4 436.9 Deferred tax asset 224.3 229.9 Prepaid expenses and other current assets 283.2 221.8 Total current assets 3,333.3 3,212.1 Non-current assets: Investments 39.3 38.7 Property, plant and equipment ("PP&E"), net 951.0 955.8 Goodwill 522.8 644.5 Other intangible assets, net 2,657.2 2,388.1 Deferred tax asset 47.3 46.5 Other non-current assets 34.7 31.5 Total assets 7,585.6 7,317.2 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses 1,477.2 1,501.5 Other current liabilities 142.5 144.1 Total current liabilities 1,619.7 1,645.6 Non-current liabilities: Convertible bonds 1,100.0 1,100.0 Deferred tax liability 607.3 520.8 Other non-current liabilities 476.5 241.6 Total liabilities 3,803.5 3,508.0 Equity: Common stock of 5p par value; 1,000 million shares authorized; and 562.8 million shares issued and outstanding (2012: 1,000 million shares authorized; and 562.5 million shares issued and outstanding) 55.7 55.7 Additional paid-in capital 3,002.1 2,981.5 Treasury stock: 11.3 million shares (2012: 10.7 million) (341.6) (310.4) Accumulated other comprehensive income 49.1 86.9 Retained earnings 1,016.8 995.5 Total equity 3,782.1 3,809.2 Total liabilities and equity 7,585.6 7,317.2
Unaudited US GAAP results for the three months to March 31, 2013
Consolidated Statements of Income
3 months to March 31, 2013 2012 $M $M Revenues: Product sales 1,116.7 1,106.9 Royalties 38.5 56.3 Other revenues 6.7 8.6 Total revenues 1,161.9 1,171.8 Costs and expenses: Cost of product sales(1) 155.9 158.4 R&D 224.2 220.3 SG&A(1) 438.7 500.0 Goodwill impairment charge 198.9 - Gain on sale of product rights (6.5) (7.2) Reorganization costs 17.5 - Integration and acquisition costs 4.1 5.3 Total operating expenses 1,032.8 876.8 Operating income 129.1 295.0 Interest income 0.7 0.8 Interest expense (9.1) (10.2) Other income, net (1.1) 1.9 Total other expense, net (9.5) (7.5) Income from continuing operations before income taxes and equity in earnings of equity method investees 119.6 287.5 Income taxes (55.2) (50.0) Equity in earnings of equity method investees, net of taxes 0.4 0.9 Net income 64.8 238.4
3 months to March 31, 2013 2012 Earnings per ordinary share - basic 11.7c 43.1c Earnings per ADS - basic 35.1c 129.3c Earnings per ordinary share - diluted 11.7c 41.4c Earnings per ADS - diluted 35.1c 124.2c Weighted average number of shares: Millions Millions Basic 551.5 553.5 Diluted(2) 555.3 595.6
Unaudited US GAAP results for the three months to March 31, 2013
Consolidated Statements of Cash Flows
3 months to March 31, 2013 2012 $M $M CASH FLOWS FROM OPERATING ACTIVITIES: Net income 64.8 238.4 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 75.0 73.0 Share based compensation 16.6 22.0 Goodwill impairment charge 198.9 - Other (4.6) (5.9) Movement in deferred taxes 1.4 (20.8) Equity in earnings of equity method investees (0.4) (0.9) Changes in operating assets and liabilities: Increase in accounts receivable (51.3) (65.2) Increase in sales deduction accrual 44.4 54.5 Increase in inventory (29.1) (25.0) (Increase)/decrease in prepayments and other assets (61.8) 17.2 Decrease in accounts and notes payable and other liabilities (93.5) (30.3) Net cash provided by operating activities(A) 160.4 257.0
CASH FLOWS FROM INVESTING ACTIVITIES: Movements in restricted cash (2.2) 5.7 Purchases of subsidiary undertakings and businesses, net of cash acquired (77.2) - Purchases of non-current investments (2.8) (4.1) Purchases of PP&E (47.3) (31.7) Purchases of intangible assets - (22.0) Proceeds received on sale of product rights 4.8 5.6 Proceeds from capital expenditure grants 2.7 8.4 Proceeds from disposal of non-current investments and PP&E 0.7 3.8 Returns from equity investments - 0.1 Net cash used in investing activities(B) (121.3) (34.2)
CASH FLOWS FROM FINANCING ACTIVITIES: Payments to acquire shares under the share buy-back program (70.6) - Deferred contingent consideration payments (6.0) - Excess tax benefit associated with exercise of stock options 4.4 34.8 Other (0.7) 0.6 Net cash (used in)/provided by financing activities(C) (72.9) 35.4 Effect of foreign exchange rate changes on cash and cash equivalents(D) 2.3 1.2 Net (decrease)/increase in cash and cash equivalents(A) +(B) +(C) +(D) (31.5) 259.4 Cash and cash equivalents at beginning of period 1,482.2 620.0 Cash and cash equivalents at end of period 1,450.7 879.4
Unaudited US GAAP results for the three months to March 31, 2013
Selected Notes to the Financial Statements
(1) Earnings Per Share ("EPS")
3 months to March 31, 2013 2012 $M $M Net Income 64.8 238.4 Numerator for basic EPS 64.8 238.4 Interest on convertible bonds, net of tax(1) - 8.4 Numerator for diluted EPS 64.8 246.8 Weighted average number of shares: Millions Millions Basic(2) 551.5 553.5 Effect of dilutive shares: Share based awards to employees(3) 3.8 8.6 Convertible bonds 2.75% due 2014(4) - 33.5 Diluted(5) 555.3 595.6
The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below:
3 months to March 31, 2013 2012 No. of No. of shares shares Millions Millions Share based awards to employees(1) 5.6 6.1 Convertible bonds 2.75% due 2014(2) 33.6 -
Unaudited US GAAP results for the three months to March 31, 2013
Selected Notes to the Financial Statements
(2) Analysis of revenues
3 months to March 31, 2013 2012 2013 2013 % % of total $M $M change revenue Net product sales: Specialty Pharmaceuticals Behavioral Health VYVANSE 298.4 260.0 15% 26% ADDERALL XR 99.8 111.4 -10% 9% INTUNIV 77.7 68.5 13% 7% EQUASYM(R) 6.7 7.2 -7% <1% 482.6 447.1 8% 42% Gastro Intestinal LIALDA/MEZAVANT 100.5 90.0 12% 9% PENTASA 71.0 65.8 8% 6% RESOLOR(R) 3.2 2.4 33% <1% 174.7 158.2 10% 15% General products FOSRENOL 42.3 45.5 -7% 4% XAGRID(R) 23.4 23.2 1% 2% 65.7 68.7 -4% 6% Other product sales 23.6 32.7 -28% 2% Total SP product sales 746.6 706.7 6% 64% Human Genetic Therapies ELAPRASE 114.3 125.6 -9% 10% REPLAGAL 114.0 134.4 -15% 10% VPRIV 81.6 71.7 14% 7% FIRAZYR 41.7 19.7 112% 3% Total HGT product sales 351.6 351.4 0% 30% Regenerative Medicine DERMAGRAFT 18.5 48.8 -62% 2% Total RM product sales 18.5 48.8 -62% 2% Total product sales 1,116.7 1,106.9 1% 96% Royalties: 3TC and ZEFFIX 12.5 13.6 -8% 1% FOSRENOL 9.0 10.0 -10% 1% ADDERALL XR 8.1 25.3 -68% <1% Other 8.9 7.4 20% 1% Total royalties 38.5 56.3 -32% 3% Other revenues 6.7 8.6 -22% <1% Total revenues 1,161.9 1,171.8 -1% 100%
Unaudited results for the three months to March 31, 2013
Non GAAP reconciliation
3 months to March 31, Non 2013 US GAAP Adjustments GAAP (a) (b) (c) (d) (e) $M $M $M $M $M $M $M Total revenues 1,161.9 - - - - - 1,161.9 Costs and expenses: Cost of product sales 155.9 - - - - (7.8) 148.1 R&D 224.2 - - - - (4.6) 219.6 SG&A 438.7 (45.9) - - (4.2) (16.7) 371.9 Gain on sale of product rights (6.5) - - 6.5 - - - Goodwill impairment charge 198.9 (198.9) - - - - - Reorganization costs 17.5 - - (17.5) - - - Integration and acquisition costs 4.1 - (4.1) - - - - Depreciation - - - - - 29.1 29.1 Total operating expenses 1,032.8 (244.8) (4.1) (11.0) (4.2) - 768.7 Operating income 129.1 244.8 4.1 11.0 4.2 - 393.2 Interest income 0.7 - - - - - 0.7 Interest expense (9.1) - - - - - (9.1) Other expense, net (1.1) - - - - - (1.1) Total other expense, net (9.5) - - - - - (9.5) Income before income taxes and equity in earnings of equity method investees 119.6 244.8 4.1 11.0 4.2 - 383.7 Income taxes (55.2) (14.6) (0.5) - (1.5) - (71.8) Equity in earnings of equity method investees, net of tax 0.4 - - - - - 0.4 Net income 64.8 230.2 3.6 11.0 2.7 - 312.3 Impact of convertible debt, net of tax (1) - 7.6 - - - - 7.6 Numerator for diluted EPS 64.8 237.8 3.6 11.0 2.7 - 319.9 Weighted average number of shares (millions) - diluted(1) 555.3 33.6 - - - - 588.9 Diluted earnings per ADS 35.1c 118.8c 1.8c 5.7c 1.5c - 162.9c
The following items are included in Adjustments:
(a) Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($45.9 million), impairment of RM goodwill ($198.9 million), and tax effect of adjustments;
(b) Acquisition and integration activities: Costs primarily associated with the acquisition of Lotus and integration of FerroKin ($2.3 million), charges related to the change in fair value of deferred contingent consideration ($1.8 million), and tax effect of adjustments;
(c) Divestments, reorganizations and discontinued operations: Re-measurement of DAYTRANA contingent consideration to fair value ($6.5 million), costs relating to the collective dismissal and closure of Shire's facility at Turnhout, Belgium ($17.5 million), and tax effect of adjustments;
(d) Legal and litigation costs: Costs related to litigation, government investigations, other disputes and external legal costs ($4.2 million), and tax effect of adjustments; and
(e) Depreciation reclassification: Depreciation of $29.1 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
Unaudited results for the three months to March 31, 2012
Non GAAP reconciliation
3 months to March 31, 2012 US GAAP Adjustments Non GAAP (a) (b) (c) (d) $M $M $M $M $M $M Total revenues 1,171.8 - - - - 1,171.8 Costs and expenses: Cost of product sales 158.4 - - - (7.2) 151.2 R&D 220.3 - (23.0) - (6.4) 190.9 SG&A 500.0 (45.6) - - (13.6) 440.8 Gain on sale of product rights (7.2) - - 7.2 - - Integration and acquisition costs 5.3 - (5.3) - - - Depreciation - - - - 27.2 27.2 Total operating expenses 876.8 (45.6) (28.3) 7.2 - 810.1 Operating income 295.0 45.6 28.3 (7.2) - 361.7 Interest income 0.8 - - - - 0.8 Interest expense (10.2) - - - - (10.2) Other income, net 1.9 - - - - 1.9 Total other expense, net (7.5) - - - - (7.5) Income before income taxes and equity in earnings of equity method investees 287.5 45.6 28.3 (7.2) - 354.2 Income taxes (50.0) (13.2) (6.6) - - (69.8) Equity in earnings of equity method investees, net of tax 0.9 - - - - 0.9 Net income 238.4 32.4 21.7 (7.2) - 285.3 Impact of convertible debt, net of tax 8.4 - - - - 8.4 Numerator for diluted EPS 246.8 32.4 21.7 (7.2) - 293.7 Weighted average number of shares (millions) - diluted 595.6 - - - - 595.6 Diluted earnings per ADS 124.2c 16.3c 10.9c (3.5c) - 147.9c
The following items are included in Adjustments:
(a) Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($45.6 million), and tax effect of adjustments;
(b) Acquisition and integration activities: Up-front payments made to Sangamo Biosciences Inc. and for the acquisition of the US rights to prucalopride (marketed in certain countries in Europe as RESOLOR) ($23.0 million), costs associated with the acquisition of FerroKin and the integration of ABH ($5.3 million); and tax effect of adjustments;
(c) Divestments, reorganizations and discontinued operations: Re-measurement of DAYTRANA contingent consideration to fair value ($7.2 million), and tax effect of adjustments; and
(d) Depreciation reclassification: Depreciation of $27.2 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.
Unaudited results for the three months to March 31, 2013
Non GAAP reconciliation
The following table reconciles US GAAP net cash provided by operating activities to Non GAAP cash generation:
3 months to March 31, 2013 2012 $M $M Net cash provided by operating activities 160.4 257.0 Tax and interest payments, net 97.1 29.8 Up-front payments in respect of in-licensed and acquired products - 23.0 Non GAAP cash generation 257.5 309.8
The following table reconciles US GAAP net cash provided by operating activities to Non GAAP free cash flow:
3 months to March 31, 2013 2012 $M $M Net cash provided by operating activities 160.4 257.0 Up-front payments in respect of in-licensed and acquired products - 23.0 Capital expenditure (47.3) (31.7) Non GAAP free cash flow 113.1 248.3
Non GAAP net cash comprises:
March 31, December 31, 2013 2012 $M $M Cash and cash equivalents 1,450.7 1,482.2 Convertible bonds (1,100.0) (1,100.0) Other debt (8.8) (9.3) Non GAAP net cash 341.9 372.9
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
http://www.shire.com
FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that:
and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.
NON GAAP MEASURES
This press release contains financial measures not prepared in accordance with US GAAP. These measures are referred to as "Non GAAP" measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effectivetax rate on Non GAAP income before income taxes and earnings/(losses) of equity method investees ("effective tax rate on Non GAAP income"); Non GAAP cost of product sales; Non GAAP research and development; Non GAAP selling, general and administrative; Non GAAP other income/expense; Non GAAP cash generation; Non GAAP free cash flow and Non GAAP net cash/(debt). These Non GAAP measures exclude the effect of certain cash and non-cash items, that Shire's management believes are not related to the core performance of Shire's business.
These Non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of Shire's performance to historical results and to competitors' results. Shire's Remuneration Committee uses certain key Non GAAP measures when assessing the performance and compensation of employees, including Shire's executive directors.
The Non GAAP measures are presented in this press release as Shire's management believe that they will provide investors with a means of evaluating, and an understanding of how Shire's management evaluates, Shire's performance and results on a comparable basis that is not otherwise apparent on a US GAAP basis, since many non-recurring, infrequent or non-cash items that Shire's management believe are not indicative of the core performance of the business may not be excluded when preparing financial measures under US GAAP.
These Non GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.
Where applicable the following items, including their tax effect, have been excluded when calculating Non GAAP earnings for both 2013 and 2012, and from our Outlook:
Amortization and asset impairments:
Acquisitions and integration activities:
Divestments, re-organizations and discontinued operations:
Legal and litigation costs:
Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US GAAP results, has been separately disclosed for the presentation of 2013 and 2012 Non GAAP earnings.
Cash generation represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, tax and interest payments.
Free cash flow represents net cash provided by operating activities, excluding up-front and milestone payments for in-licensed and acquired products, but including capital expenditure in the ordinary course of business.
A reconciliation of Non GAAP financial measures to the most directly comparable measure under US GAAP is presented on pages 18 to 20.
Growth at CER, which is a Non GAAP measure, is computed by restating 2013 results using average 2012 foreign exchange rates for the relevant period.
Average exchange rates for Q1 2013 were $1.58:£1.00 and $1.33:€1.00 (2012: $1.57:£1.00 and $1.31:€1.00).
TRADE MARKS
All trade marks designated ® and ™ used in this press release are trade marks of Shire plc or companies within the Shire group except for 3TC® and ZEFFIX® which are trade marks of GlaxoSmithKline, PENTASA® which is a registered trade mark of FERRING B.V., LIALDA® and MEZAVANT® which are trade marks of Nogra Pharma Limited and DAYTRANA® which is a trade mark of Noven Pharmaceuticals Inc. Certain trade marks of Shire plc or companies within the Shire group are set out in Shire's Annual Report on Form 10-K for the year ended December 31, 2012.
For further information please contact:
Investor Relations - Eric Rojas erojas@shire.com +1-781-482-0999 - Sarah Elton-Farr seltonfarr@shire.com +44-1256-894-157 Media - Jessica Mann jmann@shire.com +44-1256-894-280 - Gwen Fisher gfisher@shire.com +1-484-595-9836 - Jessica Cotrone jcotrone@shire.com +1-781-482-9538
Copyright 2013 PR Newswire
1 Year Shoal Point Energy Chart |
1 Month Shoal Point Energy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions